Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07217015 · ClinicalTrials.gov registry record · Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Kymera Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT07217015: Recruiting Phase 2 study of Atopic Dermatitis, sponsored by Kymera Therapeutics.

NCT07217015 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 200 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07217015, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Kymera Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

Conditions Studied

Atopic Dermatitis

Interventions

  • OTHER Placebo
  • DRUG KT-621

Study Locations (20)

California

  • Kymera Investigative Site - Freemont
  • Kymera Investigative Site - Los Angeles
  • Kymera Investigative Site - Santa Monica

Florida

  • Kymera Investigative Site - Delray Beach
  • Kymera Investigative Site - Miami
  • Kymera Investigative Site - Miramar

Michigan

  • Kymera Investigative Site - Ann Arbor
  • Kymera Investigative Site - Detroit

Texas

  • Kymera Investigative Site - San Antonio
  • Kymera Investigative Site - San Antonio

New South Wales

  • Kymera Investigative Site - Darlinghurst
  • Kymera Investigative Site - Kogarah

Alabama

  • Kymera Investigative Site - Birmingham

Arkansas

  • Kymera Investigative Site - North Little Rock

Illinois

  • Kymera Investigative Site - Normal

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-11-24
Est. Completion 2028-06
Phase Phase 2
Kymera Therapeutics

10 total trials

What NCT07217015 shows while recruiting

NCT07217015 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07217015 names 20 study sites across 13 states, led by California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT07217015 about?

NCT07217015 is a clinical study titled "A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis". This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the...

What is the current status of trial NCT07217015?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-24. Estimated completion is 2028-06.

What conditions does trial NCT07217015 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT07217015?

The interventions under investigation include: Placebo (OTHER), KT-621 (DRUG).

Who is sponsoring clinical trial NCT07217015?

This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07217015 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07217015's enrollment target sits among peer trials

200 56th of 150 higher than 89 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

  • NCT00568490 · 200 participants

    Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07217015

Source: ClinicalTrials.gov NCT07217015, the US trial registry maintained by the National Library of Medicine. NCT07217015 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.